Navigation Links
Essilor Cancels Four Million Shares
Date:7/13/2010

CHARENTON-LE-PONT, France, July 13, 2010 /PRNewswire-FirstCall/ -- On June 28, 2010, Essilor cancelled 4,000,000 shares, in line with its commitment not to create any dilution for existing shareholders. The two-part transaction was carried out as follows:

    - 2,130,000 shares were cancelled to offset the dilutive impact of the
      vesting of performance shares or the exercise of stock options granted
      to employees.

    - 1,870,000 shares were cancelled to offset the dilution resulting from
      the conversion of the now mature OCEANE convertible bonds. The shares
      had been purchased as part of a program launched in 2008 to buy back up
      to 6,900,000 shares for allocation on conversion of the OCEANE bonds
      then outstanding. To date, Essilor has bought back 5,200,000 shares
      under this program, of which 3,370,000 have now been cancelled.

The world leader in ophthalmic optical products, Essilor International researches, develops, manufactures and markets around the world a wide range of lenses to improve and protect eyesight. Its flagship brands are Varilux(R), Crizal(R), Essilor(R), Definity(R) and Xperio(TM).

Based in France, the company reported consolidated revenue of more than EUR3.2 billion in 2009, with 34,700 employees and operations in 100 countries.

For more information, please visit http://www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the CAC 40 index.

    Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

    Investor Relations and Financial Communications
    Veronique Gillet - Sebastien Leroy
    Phone: +33(0)1-49-77-42-16
    http://www.essilor.com



'/>"/>
SOURCE Essilor
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essilor - 2010 First Quarter Report
2. Essilor Acquires FGX International, Becoming a Major Player in a New Fast-Growing Market
3. iPierian Closes $22 Million Series B Financing Led By Google Ventures
4. China-Biotics, Inc. Announces US$20 million Share Buyback Program
5. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
6. DURECT Corporation Secures $50 Million Committed Equity Financing Facility
7. Bacterin International Holdings, Inc. Completes Merger and $7.5 Million Raise
8. Vermillion Announces Issuance of Patent for Alzheimers Disease Diagnosis
9. Patient Safety Technologies Completes $6.0 Million Equity Financing
10. Hanger Orthopedic Group, Inc. Announces Three Acquisitions With Annual Revenues of $14.0 Million
11. Baxano, Inc. Announces Close of $30 Million Series C Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
Breaking Medicine News(10 mins):